Literature DB >> 4122211

An established cultured cell line (HBT-39) from human breast carcinoma.

E J Plata, T Aoki, D D Robertson, E W Chu, B I Gerwin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4122211     DOI: 10.1093/jnci/50.4.849

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  Technique for cultivation of transitional epithelium from mammalian urinary bladder.

Authors:  A Y Elliott; N Stein; E E Fraley
Journal:  In Vitro       Date:  1975 Sep-Oct

2.  In vitro studies of human breast carcinoma cells obtained by aspiration biopsy.

Authors:  M Volk; H Schöndorf; H Naujoks
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-10-30

3.  Establishment and characterization of a new cell line (VHB-1) derived from a primary breast carcinoma.

Authors:  B Vandewalle; M Collyn d'Hooghe; J B Savary; M O Vilain; J P Peyrat; M Deminatti; A Delobelle-Deroide; J Lefebvre
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

4.  Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma.

Authors:  R K Young; R M Cailleau; B Mackay; W J Reeves
Journal:  In Vitro       Date:  1974 Jan-Feb

5.  Human melanoma FUHS-1. Description of a new cell line.

Authors:  V Misgeld; C Meisel
Journal:  Arch Dermatol Forsch       Date:  1975

6.  Long-term tissue cultures of human pleural effusions: a cytological follow-up.

Authors:  J Mouriquand; C Mouriquand; E Petitpas; M A Mermet
Journal:  In Vitro       Date:  1978-07

7.  Two new estrogen-supersensitive variants of the MCF-7 human breast cancer cell line.

Authors:  C Natoli; G Sica; V Natoli; A Serra; S Iacobelli
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

8.  Tumor-specific cell-mediated immunity in household contacts of cancer patients..

Authors:  V S Byers; A S Levin; A J Hackett; H H Fudenberg
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.